| 1 |
NCT03659643 |
Recruiting |
Mild Cognitive Impairment, Use of qEEG as a Prognostic Marker |
- Mild Cognitive Impairment
|
- Diagnostic Test: EEG with SPR analysis
|
Observational
|
|
- Jon Snaedal
- Ullevaal University Hospital
- Karolinska University Hospital
- (and 5 more...)
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Diagnosis of dementia
- CERAD ten word test
|
300 |
All |
50 Years to 85 Years (Adult, Older Adult) |
NCT03659643 |
NORD-MCI |
|
January 1, 2018 |
October 1, 2020 |
October 1, 2020 |
September 6, 2018 |
September 6, 2018 |
|
- Landspitali University Hospital
Reykjavík, Iceland
|
|
| 2 |
NCT03478228 |
Completed |
Multi-Sensory Training and Wrist Fractures |
|
- Other: Multi-Sensory Training
|
Interventional
|
Not Applicable |
- Landspitali University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Sensory Organization Test (SOT)
|
150 |
All |
50 Years to 75 Years (Adult, Older Adult) |
NCT03478228 |
2013 16 ÓB/eí |
|
May 15, 2015 |
May 25, 2016 |
May 25, 2016 |
March 27, 2018 |
March 27, 2018 |
|
- University of Iceland
Reykjavik, Iceland
|
|
| 3 |
NCT03327597 |
Recruiting |
Iceland Screens, Treats or Prevents Multiple Myeloma |
- Monoclonal Gammopathy of Undetermined Significance
|
- Other: Clinical follow-up 1
- Other: QoL questionnaire
- Other: Standard follow-up or treatment.
- (and 3 more...)
|
Interventional
|
Not Applicable |
- University of Iceland
- Landspitali University Hospital
- Union for International Cancer Control
- (and 7 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Screening
|
- Overall survival
- Cause specific survival
- Quality of life (QoL)
- Cost-effectiveness of screening for MGUS
|
78000 |
All |
40 Years and older (Adult, Older Adult) |
NCT03327597 |
UI-2017-MGUS |
iStopMM |
September 1, 2016 |
September 1, 2021 |
September 1, 2021 |
October 31, 2017 |
October 17, 2018 |
|
- University of Iceland
Reykjavík, Iceland
|
|
| 4 |
NCT02752633 |
Completed
Has Results |
Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion |
- Adenine Phosphoribosyltransferase Deficiency
|
- Drug: Allopurinol
- Drug: Febuxostat
|
Interventional
|
Phase 4 |
- Landspitali University Hospital
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Urinary 2,8-dihydroxyadenine Excretion
|
9 |
All |
18 Years and older (Adult, Older Adult) |
NCT02752633 |
RDCRN Protocol #6412
2013-000975-33
U54DK083908 |
|
May 2013 |
May 2015 |
May 2015 |
April 27, 2016 |
December 27, 2017 |
December 27, 2017 |
- Landspitali - The National University Hospital of Iceland
Reykjavik, Iceland
|
|
| 5 |
NCT02705664 |
Completed |
Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% |
|
- Drug: Loceryl Nail Lacquer
- Drug: Urea Ointment
- Drug: Bifonazole Cream
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- % adherent subjects with applications
- % adherent subjects with nail preparation
- % Subjects satisfied to very satisfied with each study treatment at week 7
|
22 |
All |
18 Years and older (Adult, Older Adult) |
NCT02705664 |
RD.03.SPR.105078 |
OPEN |
January 2016 |
September 2016 |
September 2016 |
March 10, 2016 |
September 16, 2016 |
|
- Principal Investigator
Reykjavik, Iceland
|
|
| 6 |
NCT02682212 |
Active, not recruiting |
Obstetric Perineal Trauma and Physiotherapy |
|
- Other: Physiotherapy intervention
|
Interventional
|
Not Applicable |
- Landspitali University Hospital
- University of Iceland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Urinary incontinence rates measured by scores on the Australian Female PelvicFloor questionnaire
- Fecal/flatal incontinence measured by scores on the Australian Female PelvicFloor questionnaire
- Sexual dysfunction measured by scores on the Australian Female PelvicFloor questionnaire
- Quality of life measured by scores on the Australian Female PelvicFloor questionnaire
|
84 |
Female |
18 Years and older (Adult, Older Adult) |
NCT02682212 |
LSH-15-001 |
|
March 16, 2016 |
July 2018 |
December 2018 |
February 15, 2016 |
November 14, 2017 |
|
- Tap, Physical Therapy Clinic
Kopavogur, Iceland
|
|
| 7 |
NCT02647879 |
Recruiting |
Treatment as Prevention for Hepatitis C in Iceland |
|
|
Observational
|
|
- Landspitali University Hospital
- SAA -National Center of Addiction Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of transmission of HCV in Iceland
- Incidence of cirrhosis and hepatocellular carcinoma in Iceland
- Sustained virological response rate (SVR) to treatment with antiviral agents as measured by negative HCV RNA 12 weeks post treatment
- Reinfection rate as measured by new infections diagnosed in patients who were previously treated and achieved SVR
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02647879 |
LSH-15-003 |
TraPHepC |
January 2016 |
December 2018 |
May 2031 |
January 6, 2016 |
August 17, 2018 |
|
- Landspitali
Reykjavik, Iceland
|
|
| 8 |
NCT02321098 |
Completed
Has Results |
Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish |
|
- Drug: Loceryl NL + Cosmetic varnish
- Drug: Loceryl NL 12 weeks
- Drug: Loceryl NL 15 months
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Measurement of Antifungal Activity of Loceryl Nail Lacquer
- Absence of Dermatophytes in Nail Samples Culture
|
50 |
All |
18 Years and older (Adult, Older Adult) |
NCT02321098 |
RD.03.SPR29106
2013-000544-26 |
COOL |
February 2014 |
January 2016 |
January 2016 |
December 22, 2014 |
October 9, 2018 |
October 9, 2018 |
- Principal Investigator
Reykjavik, Iceland
|
|
| 9 |
NCT02301273 |
Completed |
Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy |
|
- Other: Usual Physiotherapy
- Other: Enhanced Physiotherapy
|
Interventional
|
Not Applicable |
- Landspitali University Hospital
- University of Iceland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Length of ICU and hospital stay
- Physical Function
- Physical function
- Health Related Quality of Life
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02301273 |
16.2011 |
|
November 2011 |
November 2015 |
November 2015 |
November 25, 2014 |
November 30, 2015 |
|
- Landspítali University Hospital
Reykjavík, Iceland
|
|
| 10 |
NCT02251496 |
Completed |
COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks. |
|
- Other: In between meals snacks (Snacks-group)
- Other: Oral nutrition supplement (ONS-group)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Weight changes
- Health related quality of life (HRQoL)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT02251496 |
COPD-141316051 |
COPD |
September 2014 |
December 2017 |
December 2017 |
September 29, 2014 |
May 7, 2018 |
|
- The Department of Thoracic Medicine at Landspítali
Reykjavík, Iceland
|
|
| 11 |
NCT02236455 |
Completed |
Effects of Complementary Therapies Delivered Via Mobile Technologies |
- Acute Pain
- Anxiety
- Self Efficacy
|
- Behavioral: Audio Relaxation Technique
- Behavioral: Medical Music Intervention
- Behavioral: Nature Therapy without Music
- Behavioral: Nature Therapy with Music
|
Interventional
|
Not Applicable |
- University of San Francisco
- Fulbright
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Change from baseline state anxiety via the State Trait Anxiety Scale (STAI)
- Change in baseline pain level using the Numeric Rating Scale (NRS)
|
105 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02236455 |
S5862 |
|
March 2012 |
December 2012 |
December 2012 |
September 10, 2014 |
September 10, 2014 |
|
- Landspítala
Reykjavik, Iceland
|
|
| 12 |
NCT01917591 |
Completed |
Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study |
- Punch Biopsy Wounds
- Healing Times
|
- Device: Punch biopsies treated with MariGen Wound ECM dressing
- Device: Punch biopsies treated with Oasis ECM dressing
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- wound healing
- Autoimmune investigations
- Incidence of erythema
- (and 2 more...)
|
81 |
All |
18 Years and older (Adult, Older Adult) |
NCT01917591 |
KS-0070 |
|
January 2013 |
June 2013 |
July 2013 |
August 6, 2013 |
March 3, 2017 |
|
- Læknastofur Skipholti
Reykjavik, Iceland
|
|
| 13 |
NCT01565239 |
Completed |
Fiix-prothrombin Time for Monitoring Warfarin |
- Thromboembolism
- Arterial
- Venous
|
- Device: Fiix prothrombin time
|
Interventional
|
Phase 2 |
- Landspitali University Hospital
- University of Rochester
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Thromboembolic events
- Major hemorrhage
- Monitoring test frequency and time spent within target range
|
1156 |
All |
18 Years and older (Adult, Older Adult) |
NCT01565239 |
Landspitali-1 |
Fiix |
March 2012 |
February 2014 |
February 2014 |
March 28, 2012 |
September 9, 2014 |
|
- Landspitali University Hospital
Reykjavik, N.a., Iceland
|
|
| 14 |
NCT01391741 |
Completed |
The Effect of High-Volume Walking With Visual Cues (VC) in Parkinson´s Disease (PD) |
|
- Other: Visual Cues
- Other: Walking without visual cues
|
Interventional
|
Phase 3 |
- University of Iceland
- The Icelandic Parkinson´s Association.
- Icelandic Physiotherapy Association
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Step Length
- Change in Gait Velocity
- Change in Stride Time Variability
- Change in Timed Up & Go (seconds)
|
26 |
All |
up to 79 Years (Child, Adult, Older Adult) |
NCT01391741 |
123SmOkE |
|
April 2008 |
September 2008 |
September 2008 |
July 12, 2011 |
July 12, 2011 |
|
- Reykjalundur Rehabilitation Center
Mosfellsbaer, Iceland
|
|
| 15 |
NCT01348581 |
Completed |
Use of Fish Skin Extracellular Matrix (ECM) to Facilitate Chronic Wound Healing |
- Pressure Ulcers
- Venous Ulcers
- Diabetic Ulcers
- (and 2 more...)
|
- Device: Marigen Wound Dressing
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Wound healing
- Wound granulation
|
37 |
All |
18 Years and older (Adult, Older Adult) |
NCT01348581 |
KERECIS-10-106-S1
MW-ECM |
|
November 2010 |
December 2012 |
January 1, 2013 |
May 5, 2011 |
March 3, 2017 |
|
- National University Hospital
Reykjavik, Iceland
|
|
| 16 |
NCT01322568 |
Completed |
Research on Aging Project in Iceland: Second Stage |
- Atherosclerosis
- Osteoporosis
- Obesity
- (and 3 more...)
|
|
Observational
|
|
- National Institute on Aging (NIA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Time Perspective: Prospective
|
|
5764 |
All |
32 Years to 60 Years (Adult) |
NCT01322568 |
999903319
03-AG-N319 |
|
January 31, 2003 |
|
February 11, 2014 |
March 24, 2011 |
September 3, 2018 |
|
- Icelandic Heart Association Research Institute
Kopavogur, Iceland
|
|
| 17 |
NCT01100853 |
Completed
Has Results |
Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland |
|
- Drug: VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
|
Interventional
|
Phase 3 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
- Society of Alcoholism and other Addictions
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number Negative Urines (Proportion Negative Urines)
- Number Negative Urines (Proportion Negative Urines) Amphetamine
- Amphetamine Craving Scale
- (and 3 more...)
|
100 |
All |
18 Years and older (Adult, Older Adult) |
NCT01100853 |
811095
P50DA012756
2009-013647-10 |
|
May 2010 |
February 2013 |
February 2013 |
April 9, 2010 |
March 6, 2018 |
January 13, 2014 |
- SAA National Center of Addiction Medicine, Vogur Hospital
Storhofda 45, Reykjavík, Iceland
|
|
| 18 |
NCT01074879 |
Completed |
Protein Ingestion and Resistance Exercise in Elderly |
|
- Dietary Supplement: Whey protein
- Dietary Supplement: Milk protein
- Dietary Supplement: Carbohydrates
|
Interventional
|
Not Applicable |
- University of Iceland
- Landspitali University Hospital Research Fund
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
|
220 |
All |
65 Years and older (Older Adult) |
NCT01074879 |
071323007 |
IceProQualita |
August 2008 |
December 2009 |
December 2009 |
February 24, 2010 |
February 24, 2010 |
|
- Unit for Nutrition Research
Reykjavik, Iceland
|
|
| 19 |
NCT00853749 |
Completed
Has Results |
Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine |
- Invasive Pneumococcal Disease
|
- Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)
- Procedure: Blood draw
|
Interventional
|
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
- Pfizer
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per Milliliter (Mcg/mL) Measured 1 Month After Vaccination
- Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥ 1:8 Measured 1 Month After Vaccination
- Antibody Response Measured 1 Month After Vaccination (Avidity Assay)
- Antibody Response Measured 1 Month After Vaccination (OPA)
|
89 |
All |
5 Years to 8 Years (Child) |
NCT00853749 |
6096A1-3013
B1851012 |
REPLAY |
May 2009 |
August 2010 |
August 2010 |
March 2, 2009 |
January 5, 2011 |
January 5, 2011 |
- Pfizer Investigational Site
Reykjavik, Iceland
|
|
| 20 |
NCT00346008 |
Completed |
Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members |
|
- Genetic: mutation analysis
- Other: high performance liquid chromatography
- Other: laboratory biomarker analysis
- Other: questionnaire administration
|
Observational
|
|
- Iceland Genomics Corporation
- National Cancer Institute (NCI)
|
Industry / NIH |
|
- Feasibility to identify melanoma
- Feasibility to detect mutation
- Ability to create datasets
|
2500 |
All |
Child, Adult, Older Adult |
NCT00346008 |
NBCI-03-033-CM
NCI-06-C-N026
CDR0000551606
NBCI-01-087-CM
999906026 |
|
October 2005 |
December 2008 |
February 2009 |
June 29, 2006 |
May 30, 2013 |
|
- Iceland Genomics Corporation
Reykjavik, Iceland
|
|
| 21 |
NCT03272516 |
Recruiting |
Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients |
|
- Behavioral: Mindfulness based cognitive therapy (MBCT)
- Other: Treatment as usual (TAU)
|
Interventional
|
Not Applicable |
- University of Iceland
- University of Aarhus
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Health Services Research
|
- Symptoms of depression measured with the PHQ-9 questionnaire
- Symptoms of anxiety measured with the GAD-7 questionnaire
- Subjective well-being measured with the SWEMWBS questionnaire
- (and 2 more...)
|
165 |
All |
18 Years to 67 Years (Adult, Older Adult) |
NCT03272516 |
UI-2017-MBCT. |
|
September 12, 2017 |
October 10, 2019 |
October 10, 2019 |
September 5, 2017 |
October 11, 2018 |
|
- Heilsugæslan Grafarvogi
Reykjavík, Grafarvogur, Iceland - Heilsugæslan Miðbæ
Reykjavík, Iceland
|
|
| 22 |
NCT03661242 |
Not yet recruiting |
Integration of Exercise Into Cancer Care: A Shared Care Model |
|
- Behavioral: Physical activity
|
Interventional
|
Not Applicable |
- Landspitali University Hospital
- Gundersen Health System
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Functional Assessment of Cancer Therapy - General (FACT-G QOL) measurement.
- 6-minute walk test
- International Physical Activity Questionnaire (IPAQ) score
- Patient Health Questionnaire 9 (PHQ-9) score
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03661242 |
LSH-18-001 |
|
October 1, 2018 |
December 31, 2022 |
December 31, 2022 |
September 7, 2018 |
September 13, 2018 |
|
- Gundersen Health System
La Crosse, Wisconsin, United States - Landspitali - The National University Hospital of Iceland
Reykjavik, Iceland
|
|
| 23 |
NCT03176732 |
Recruiting |
Mechanisms for Individual Differences in Hypertension in Obstructive Sleep |
- Sleep Apnea, Obstructive
- Hypertension
|
- Device: Positive Airway Pressure
|
Observational
|
|
- University of Pennsylvania
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Nocturnal mean arterial blood pressure (nMAP)
- Oxidative stress
- Sympathetic activity
|
200 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03176732 |
823172
P01HL094307-06A1 |
PISA-BP |
June 6, 2017 |
September 30, 2021 |
September 30, 2021 |
June 5, 2017 |
June 21, 2018 |
|
- University of Pennsylvania
Philadelphia, Pennsylvania, United States - University of Iceland
Reykjavík, Iceland
|
|
| 24 |
NCT02124395 |
Recruiting |
Health-related Quality of Life in Rare Kidney Stone |
- Primary Hyperoxaluria
- Cystinuria
- Adenine Phosphoribosyl Transferase Deficiency
- Dent Disease
|
- Other: Health-related Quality of Life in Rare Kidney Stone Questionnaire
|
Observational
|
|
- New York University School of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Assessment of HRQoL in patients with rare kidney stones
|
320 |
All |
5 Years and older (Child, Adult, Older Adult) |
NCT02124395 |
13-00968
1U54DK083908-01 |
|
August 2013 |
September 2018 |
September 2018 |
April 28, 2014 |
November 22, 2017 |
|
- Primary Hyperoxaluria and Dent Disease Registry - Mayo Clinic
Rochester, Minnesota, United States - New York University School of Medicine - Cystinuria Registry
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
|
| 25 |
NCT00449553 |
Completed |
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. |
|
- Drug: Pioglitazone and sulphonylurea
- Drug: Pioglitazone and metformin
|
Observational
|
|
- Takeda
- Eli Lilly and Company
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change from baseline in glycosylated hemoglobin.
- Change from baseline in Clinical Laboratory Tests (alanine transaminase, hematocrit and hemoglobin).
- Change from baseline in Body Weight.
- (and 4 more...)
|
326 |
All |
18 Years and older (Adult, Older Adult) |
NCT00449553 |
H6E-CP-GLAR
U1111-1114-2473 |
|
June 2001 |
September 2003 |
September 2003 |
March 20, 2007 |
February 28, 2012 |
|
- Multiple, Denmark
- Multiple, Iceland
- Multiple, Norway
- Multiple, Sweden
|
|
| 26 |
NCT01088217 |
Recruiting |
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) |
- Idiopathic Pulmonary Fibrosis
- Familial Pulmonary Fibrosis
- Idiopathic Interstitial Pneumonia
- Familial Interstitial Pneumonia
|
|
Observational
|
|
- National Jewish Health
- University of Colorado, Denver
- Vanderbilt University
- Landspitali University Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Cross-Sectional
|
- Identify a group of genetic loci that play a role in the development of familial interstitial pneumonia and idiopathic interstitial pneumonia.
- Develop biomarkers using proteomic and genomic approaches that will facilitate establishing the diagnosis and prognosis of both familial and sporadic forms of idiopathic interstitial pneumonia (IIP).
|
8000 |
All |
Child, Adult, Older Adult |
NCT01088217 |
2R01HL097163 |
GWAS |
July 2008 |
June 2019 |
June 2019 |
March 17, 2010 |
March 29, 2018 |
|
- University of Colorado Denver
Aurora, Colorado, United States - National Jewish Health and University of Colorado Denver
Denver, Colorado, United States - Vanderbilt University
Nashville, Tennessee, United States - Landspitali University Hospital
Reykjavik, Iceland
|
|
| 27 |
NCT00697242 |
Completed |
Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults |
|
- Biological: Engerix™-B
- Biological: Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Anti-hepatitis B surface antigen (HBs) antibody concentrations
- Anti-pre-S1 antibody concentrations
- Anti-HBs antibody concentrations
- (and 4 more...)
|
362 |
All |
50 Years to 70 Years (Adult, Older Adult) |
NCT00697242 |
208129/009 |
|
January 1994 |
November 1995 |
November 1995 |
June 13, 2008 |
June 13, 2008 |
|
- GSK Clinical Trials Call Center
Wien, Austria - GSK Clinical Trials Call Center
Gent, Belgium - GSK Clinical Trials Call Center
Hvidovre, Denmark - GSK Clinical Trials Call Center
Reykjavik, Iceland
|
|
| 28 |
NCT00588562 |
Recruiting |
Rare Kidney Stone Consortium Patient Registry |
- Primary Hyperoxaluria
- Dent Disease
- Cystinuria
- APRT Deficiency
|
|
Observational
|
|
- Mayo Clinic
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Oxalosis and Hyperoxaluria Foundation (OHF)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Other
|
- Establish and expand registries and collaborate with patient organizations for the rapid dissemination of knowledge
- Improved understanding of symptoms and progression of four major diseases of hereditary nephrolithiasis.
|
730 |
All |
up to 100 Years (Child, Adult, Older Adult) |
NCT00588562 |
11-001702
1U54DK083908-01 |
RKSC |
July 2003 |
June 2019 |
June 2019 |
January 8, 2008 |
August 4, 2017 |
|
- Dent Disease Registry -Mayo Clinic
Rochester, Minnesota, United States - Primary Hyperoxaluria Registry - Mayo Clinic
Rochester, Minnesota, United States - Cystinuria Registry - New York University
New York, New York, United States - APRT Registry - Landspitali Universtiy Hospital
Reykjavik, Iceland
|
|
| 29 |
NCT03545659 |
Recruiting |
Childhood Acute Lymphoblastic Leukaemia: Follow-Up |
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Recurrence
|
- Other: Mode of relapse detection
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
|
400 |
All |
1 Year to 18 Years (Child, Adult) |
NCT03545659 |
ALL-Relapse |
|
September 4, 2018 |
September 2019 |
October 2019 |
June 4, 2018 |
September 6, 2018 |
|
- Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital
Aarhus N, Denmark - Department of Paediatrics and Adolescent Medicine, Turku University Hospital
Turku, Finland - The National University Hospital of Iceland
Reykjavík, Iceland - (and 2 more...)
|
|
| 30 |
NCT01305655 |
Completed
Has Results |
Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL |
- Acute Lymphoblastic Leukemia (ALL)
|
|
Interventional
|
Phase 3 |
- Nordic Society for Pediatric Hematology and Oncology
- Lund University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Event to HD-MTX Treatment in NOPHO ALL-2008 as a Measure of Toxic Mtx Concentrations in Blood, Nephrotoxicity, Hepatotoxicity, Mucositis, MTX Elimination Time and Permanent Kidney Damage.
|
47 |
All |
1 Year to 18 Years (Child, Adult) |
NCT01305655 |
NOPHO2008CPG2 |
NOPHOCPG2 |
July 2008 |
December 2014 |
December 2014 |
March 1, 2011 |
September 28, 2018 |
February 3, 2017 |
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University of Reykjavik
Reykjavik, Iceland - (and 2 more...)
|
|
| 31 |
NCT00991744 |
Suspended |
Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) |
- Acute Lymphoblastic Leukemia
|
- Drug: Liposomal cytarabine
- Drug: Intrathecal triple
|
Interventional
|
Phase 3 |
- Nordic Society for Pediatric Hematology and Oncology
- Oulu University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of leukemia relapses in the central nervous system
- Neurological toxicity
|
100 |
All |
1 Year to 18 Years (Child, Adult) |
NCT00991744 |
NOPHOALL2008-DepoCyte |
|
January 2009 |
December 2018 |
December 2018 |
October 8, 2009 |
October 10, 2012 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University of Reykjavik, Iceland
Reykjavik, Iceland - (and 2 more...)
|
|
| 32 |
NCT01327846 |
Active, not recruiting |
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) |
|
- Drug: Canakinumab
- Drug: Placebo
- Drug: Standard of care
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Main:Time to first occurrence of major adverse cardiovascular event, which is a composite of CV death, non-fatal MI, and stroke.
- Substudy 1; Change from baseline in carotid plaque burden in the bifurcation region of the index carotid artery
- Substudy 2; Change from baseline of the insulin secretion rate (ISR) relative to glucose 0-30 min defined as Φ30 = AUCISR 0-30 / AUCGluc 0-30 averaged across the yearly visits.
- (and 12 more...)
|
10061 |
All |
18 Years and older (Adult, Older Adult) |
NCT01327846 |
CACZ885M2301
2010-022970-14 |
CANTOS |
April 11, 2011 |
March 28, 2017 |
March 2, 2020 |
April 4, 2011 |
August 21, 2018 |
|
- Novartis Investigative Site
Athens, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - (and 1130 more...)
|
|
| 33 |
NCT01035255 |
Terminated
Has Results |
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure |
- Heart Failure With Reduced Ejection Fraction
|
- Drug: LCZ696 200 mg BID
- Drug: Enalapril 10 mg BID
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization
- Number of Patients - All-cause Mortality
- Number of Patients Reported With Adjudicated Primary Causes of Death
- (and 3 more...)
|
8442 |
All |
18 Years and older (Adult, Older Adult) |
NCT01035255 |
CLCZ696B2314
2009-015834-31 |
PARADIGM-HF |
December 2009 |
May 2014 |
May 2014 |
December 18, 2009 |
August 15, 2016 |
September 7, 2015 |
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Huntsville, Alabama, United States - (and 1027 more...)
|
|
| 34 |
NCT00224484 |
Completed
Has Results |
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old |
|
- Biological: GSK208141
- Biological: HavrixTM (investigational formulation)
- Biological: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Number of Subjects With Serious Adverse Events (SAEs)
- Number of Subjects With Any and Grade 3 Solicited Local Symptoms
- Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
- (and 7 more...)
|
5960 |
Female |
10 Years to 17 Years (Child) |
NCT00224484 |
208141/040 |
|
April 2004 |
July 2007 |
July 2007 |
September 23, 2005 |
April 10, 2017 |
April 10, 2017 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Chandler, Arizona, United States - (and 149 more...)
|
|
| 35 |
NCT02900378 |
Completed |
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure |
- Chronic Heart Failure With Reduced Ejection Fraction
|
- Drug: LCZ696 (sacubitril/valsartan)
- Drug: Placebo to LCZ696 (sacubitril/valsartan)
- Drug: Enalapril
- Drug: Placebo to enalapril
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in mean daily non-sedentary daytime activity between baseline and end of study
- Percentage of patients with improved symptoms of heart failure as assessed by Patient's Global Assessment
- Change from baseline in mean daily non-sedentary daytime activity in weekly and two-weekly intervals
- (and 7 more...)
|
620 |
All |
18 Years and older (Adult, Older Adult) |
NCT02900378 |
CLCZ696B3301
2016-003085-32 |
OUTSTEP-HF |
December 20, 2016 |
April 11, 2018 |
April 11, 2018 |
September 14, 2016 |
October 10, 2018 |
|
- Novartis Investigative Site
Edegem, Antwerpen, Belgium - Novartis Investigative Site
Dendermonde, Belgium - Novartis Investigative Site
Geel, Belgium - (and 122 more...)
|
|
| 36 |
NCT01764633 |
Completed
Has Results |
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk |
|
- Biological: Evolocumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization
- Time to Cardiovascular Death, Myocardial Infarction, or Stroke
- Time to Cardiovascular Death
- (and 6 more...)
|
27564 |
All |
40 Years to 85 Years (Adult, Older Adult) |
NCT01764633 |
20110118
2014/01/004324
2012-001398-97 |
FOURIER |
February 8, 2013 |
November 11, 2016 |
November 11, 2016 |
January 9, 2013 |
February 15, 2018 |
February 15, 2018 |
- Research Site
Birmingham, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Huntsville, Alabama, United States - (and 1284 more...)
|
|
| 37 |
NCT01369329 |
Completed
Has Results |
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) |
- Crohn's Disease
- IBD
- Colitis
- Inflammatory Bowel Disease
|
- Drug: Group 2 ustekinumab 130 mg
- Drug: Group 3: ustekinumab approximately 6 mg/kg
- Drug: Group 1: Placebo
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Clinical Response at Week 6
- Number of Participants in Clinical Remission at Week 8
- Number of Participants in Clinical Response at Week 8
- (and 2 more...)
|
769 |
All |
18 Years and older (Adult, Older Adult) |
NCT01369329 |
CR018415
CNTO1275CRD3001
2010-022758-18 |
|
July 2011 |
June 2013 |
July 2013 |
June 8, 2011 |
December 7, 2016 |
December 7, 2016 |
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- La Jolla, California, United States
- (and 174 more...)
|
|
| 38 |
NCT00268216 |
Completed |
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- All cause mortality at 3 years
- Rate of moderate and severe COPD exacerbations and health status assessed by the St. George's Respiratory Questionnaire.
|
6228 |
All |
40 Years to 80 Years (Adult, Older Adult) |
NCT00268216 |
SCO30003 |
|
September 2000 |
November 2005 |
November 2005 |
December 22, 2005 |
January 20, 2017 |
|
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - (and 456 more...)
|
|
| 39 |
NCT00252824 |
Completed |
STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma |
|
- Drug: Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to first severe asthma exacerbation
- Number of asthma exacerbations
- Mean use of as-needed medication
- (and 5 more...)
|
1000 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT00252824 |
D5890L00014
STYLE |
|
July 2005 |
|
December 2006 |
November 15, 2005 |
January 24, 2011 |
|
- Research Site
Quillota, Chile - Research Site
Valparaiso, Chile - Researh Site
Dubrovnik, Croatia - (and 50 more...)
|
|
| 40 |
NCT00251914 |
Completed |
Nexium Dyspepsia/AST |
- Gastrointestinal Disease
- Signs and Symptoms, Digestive
- Dyspepsia
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary outcome is whether the patient is a responder or not after 8 weeks treatment.
- The primary efficacy outcome is based on symptom score recorded daily during the study in a patient diary.
- The patient will judge their symptoms of pain or burning centered in the upper abdomen on a four-graded scale (none, mild, moderate or severe).
- (and 3 more...)
|
1500 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT00251914 |
SD-NED-0021
D9610C00021 |
|
December 2002 |
January 2005 |
January 2005 |
November 11, 2005 |
January 24, 2011 |
|
- Research Site
Buenos Aires, Argentina - Research Site
Mendoza, Argentina - Research Site
Rosario, Argentina - (and 214 more...)
|
|
| 41 |
NCT00159835 |
Completed |
Atorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD |
|
- Drug: atorvastatin
- Drug: simvastatin
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Time to of a major coronary event: 1) non-fatal acute myocardial infarction 2) coronary death 3) resuscitated cardiac arrest
- 1) Time to any CHD event, 2) Time to Hospitalization with primary diagnosis of CHF, 3) Time to Cerbrovascular Event, 4) Time to PAD, 5) Time to any CV event and 6) All Cause Mortality
|
8600 |
All |
up to 80 Years (Child, Adult, Older Adult) |
NCT00159835 |
ATV-N-98-001
A2581145 |
IDEAL |
February 1999 |
|
March 2005 |
September 12, 2005 |
April 22, 2015 |
|
- Pfizer Investigational Site
Arhus C, Denmark - Pfizer Investigational Site
Copenhagen, Denmark - Pfizer Investigational Site
Esbjerg, Denmark - (and 191 more...)
|
|
| 42 |
NCT02563717 |
Recruiting |
Comparison Of Respiratory Support After Delivery on Infants Born Before 28 Weeks Gestational Age |
- Respiration; Insufficient or Poor, Newborn
- Infant, Premature, Diseases
|
- Device: T-piece used for respiratory support (several manufacturers)
- Device: New system used for respiratory support
|
Interventional
|
Not Applicable |
- Baldvin Jonsson
- Karolinska Institutet
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Delivery room intubation or death
- Time to primary outcome (intubation or death)
- Death
- (and 4 more...)
|
250 |
All |
Child, Adult, Older Adult |
NCT02563717 |
2015/927-31/4 |
CORSAD |
March 2016 |
December 2018 |
December 2018 |
September 30, 2015 |
December 13, 2017 |
|
- Department of neonatology, University Hospital of Iceland
Reykjavík, Iceland - Neonatal Unit, Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania - Stavanger University Hospital, Department of Pediatrics
Stavanger, Norway - (and 3 more...)
|
|
| 43 |
NCT00819351 |
Completed |
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase |
- Acute Lymphoblastic Leukemia
|
- Drug: PEG Asparaginase at six weeks interval
- Drug: PEG Asparaginase at two weeks interval
|
Interventional
|
Phase 3 |
- Rigshospitalet, Denmark
- Nordic Society for Pediatric Hematology and Oncology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival
- Secondary Outcome Measures are toxicity (special focus on thrombosis, pancreatitis, and allergic reactions), the formation of silent antibodies, and the influence of antibody production on the EFS.
|
650 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00819351 |
NOPHO ALL2008 PEG Asparaginase |
|
January 1, 2009 |
March 2, 2016 |
March 2, 2016 |
January 9, 2009 |
April 21, 2017 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University Hospital Reykjavik, Iceland
Reykjavik, Iceland - (and 3 more...)
|
|
| 44 |
NCT00816049 |
Completed |
ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy |
- Acute Lymphoblastic Leukemia
|
- Drug: 6MPindividualized
- Drug: 6MPfixed
|
Interventional
|
Phase 3 |
- Rigshospitalet, Denmark
- Nordic Society for Pediatric Hematology and Oncology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Fraction of patients that become MRD-negative at treatment days 85 and/or 92 (end-of-consolidation) and event-free survival. MRD is measured either by Flow-cytometry (for PreB-ALL patients) or PCR for clonal generearrangements(for T-ALL patients)
- Toxicity of treatment, degree of myelo-, hepato- and renal toxicity; and development of asparaginase antibodies.
|
775 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00816049 |
NOPHO ALL2008 consolidation |
ALL2008con |
January 2009 |
March 2, 2016 |
March 2, 2016 |
December 31, 2008 |
April 21, 2017 |
|
- Department of Pediatrics, Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - University Hospital
Reykjavik, Iceland - (and 3 more...)
|
|
| 45 |
NCT01025804 |
Completed |
Pharmacokinetics of Asparaginase and Antibody Formation in Interfant-06 |
|
|
Observational
|
|
- Aarhus University Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- pharmacokinetics, antibody formation, side effects
|
15 |
All |
up to 1 Year (Child) |
NCT01025804 |
Interfant-06, NOPHO
register identifier |
|
December 2009 |
December 2014 |
December 2015 |
December 4, 2009 |
March 4, 2016 |
|
- Aarhus University Hospital, Department of Pediatrics Skejby Hospital
Aarhus, Aarhus N, Denmark - Rigshospitalet
Copenhagen, Denmark - Helsinki University Hospital
Helsinki, Finland - (and 3 more...)
|
|
| 46 |
NCT03445923 |
Recruiting |
Can Time-lapse Parameters be Used to Predict Pregnancy of Human Embryos? |
|
- Other: Time lapse monitoring (KID Score)
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Ongoing pregnancy (week 6-7)
- Positive pregnancy tests, 18 days after embryo transfer.
- Early pregnancy loss (positive pregnancy test but no gestational sac observed at sonography)
- Correlation between the preliminary decisions of embryo fate based only on morphology and the final decision made by time-lapse
|
1650 |
All |
20 Years to 45 Years (Adult) |
NCT03445923 |
954-17 |
|
May 29, 2018 |
September 2020 |
September 2020 |
February 26, 2018 |
September 26, 2018 |
|
- Livio Reykjavik
Reykjavík, Iceland - Livio Oslo
Oslo, Norway - Livio Falun
Falun, Sweden - (and 7 more...)
|
|
| 47 |
NCT01587378 |
Completed |
Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome |
- Pregnancy
- Polycystic Ovary Syndrome
|
- Drug: Metformin
- Drug: placebo
|
Interventional
|
Not Applicable |
- Norwegian University of Science and Technology
- Vestre Viken Hospital Trust
- Landspitali University Hospital
- (and 11 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- combined incidence of late miscarriages and preterm births
- NICU admissions and total number of days in NICU/baby
- number of patients hospitalized
- (and 4 more...)
|
489 |
Female |
18 Years to 45 Years (Adult) |
NCT01587378 |
2011/1434
2011-002203-15 |
PregMet2 |
October 2012 |
August 2017 |
October 1, 2017 |
April 30, 2012 |
October 6, 2017 |
|
- Landspital University Hospital
Reykjavik, Iceland - Haukeland University Hospital
Bergen, Norway - Nordlandssykehuset HF
Bodø, Norway - (and 10 more...)
|
|
| 48 |
NCT02166736 |
Completed |
Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome |
- Angina Pectoris
- Acute Myocardial Infarction
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All cause death, non-fatal Myocardial infarction (MI), Unplanned revascularization
- All cause death
- Non-fatal MI
- (and 6 more...)
|
2037 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02166736 |
U-2013-044 |
iFR Swedeheart |
May 2014 |
October 2015 |
December 2016 |
June 18, 2014 |
January 12, 2017 |
|
- Skejby University Hospital
Aarhus, Denmark - Reykjavik University Hospital
Reykjavik, Iceland - Sahlgrenska University Hospital
Göteborg, Sweden - (and 11 more...)
|
|
| 49 |
NCT01093404 |
Completed |
Thrombus Aspiration in Myocardial Infarction |
- Acute Myocardial Infarction
|
- Procedure: Thrombus aspiration
|
Interventional
|
Not Applicable |
- Region Örebro County
- Uppsala University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- All-cause death
- Time to re-hospitalization with nonfatal reinfarction, heart failure and target vessel revascularization
- Time to all-cause death or new myocardial infarction (first occurring) or in hospital treatment for heart failure
- (and 3 more...)
|
7243 |
All |
18 Years and older (Adult, Older Adult) |
NCT01093404 |
SCAAR-001 |
TASTE |
July 2010 |
March 2013 |
August 2013 |
March 25, 2010 |
July 11, 2016 |
|
- Skejby Hospital, Aarhus University Hospital
Aarhus, Denmark - Landspitali University Hospital
Reykjavik, Iceland - Södra Älvsborgs sjukhus
Borås, Sweden - (and 26 more...)
|
|
| 50 |
NCT02382718 |
Completed |
FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy |
|
- Biological: FAST fish mCyp c 1
- Biological: Placebo
|
Interventional
|
Phase 2 |
- George Stavroulakis
- Hospital San Carlos, Madrid
- Odense University Hospital OUH Denmark
- (and 8 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Efficacy of subcutaneous immunotherapy with mCyp c 1 for the treatment of fish allergy (change from baseline in the threshold of fish protein that induces an allergic reaction)
- Safety (recording of adverse events)- Number of participants with adverse events and recording of the nature of adverse events
- Severity of reaction in food challenge
- (and 3 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02382718 |
FAST2015 |
FASTIIb |
October 2015 |
February 2017 |
April 2017 |
March 9, 2015 |
June 12, 2017 |
|
- National University Hospital NUHD Denmark
Gentofte, Denmark - Odense University Hospital OUH Denmark
Odense, Denmark - Sotiria General Hospital for the Diseases of the Thorax
Athens, Greece - (and 6 more...)
|
|
| 51 |
NCT02523339 |
Active, not recruiting |
Study of Retinal Oxygenation in Central Retinal Vein Occlusion |
|
|
Observational
|
|
- University of Iceland
- University Hospital, Basel, Switzerland
- Aston University
- (and 6 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Retinal vessel oxygen saturation
- Visual acuity
- Central retinal thickness
- Presence or absence of ocular neovascularisation
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT02523339 |
UI-CRVO-2015 |
|
October 2014 |
June 2018 |
December 31, 2018 |
August 14, 2015 |
July 11, 2018 |
|
- Department of Clinical Pharmacology, Medical University of Vienna
Vienna, Austria - Department of Ophthalmology, University Hospital and Faculty of Medicine and Dentistry, Palacky University Olomouc
Olomouc, Czechia - Aarhus University. Department of Clinical Medicine - The Department of Ophthalmology
Aarhus, Denmark - (and 5 more...)
|
|
| 52 |
NCT00883792 |
Active, not recruiting |
The Northern-European Initiative on Colorectal Cancer |
|
|
Interventional
|
Phase 3 |
- Oslo University Hospital
- Maria Sklodowska-Curie Institute - Oncology Center
- Erasmus Medical Center
- (and 5 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Comparison of the screening group vs. the control group in an intention-to-treat model after 15 years of follow-up with regard to CRC mortality and CRC incidence
- CRC mortality and CRC incidence of screening attendees compared to the control group and non-attendees
- Mortality from all causes
|
95000 |
All |
55 Years to 64 Years (Adult) |
NCT00883792 |
NordICC |
NordICC |
May 2009 |
June 2026 |
July 2036 |
April 20, 2009 |
June 19, 2017 |
|
- Harvard School of Public Health
Boston, Massachusetts, United States - Memorial Sloan-Kettering Cancer Center
New York, New York, United States - Landspitali University Hospital
Reykjavik, Iceland - (and 4 more...)
|
|
| 53 |
NCT00777946 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone |
|
- Drug: Aliskiren 300 mg
- Drug: Aliskiren/Amlodipine 300/5 mg
- Drug: Aliskiren/Amlodipine 300/10 mg
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline to End of Study in the Mean Sitting Diastolic Blood Pressure (msDBP)
- Change From Baseline to End of Study in the Mean Sitting Systolic Blood Pressure (msSBP)
- Number of Participants With Serious Adverse Events and Adverse Events
- (and 3 more...)
|
818 |
All |
18 Years and older (Adult, Older Adult) |
NCT00777946 |
CSPA100A2303 |
|
October 2008 |
May 2009 |
May 2009 |
October 22, 2008 |
July 12, 2011 |
June 15, 2011 |
- Investigative site
Estonia, Estonia - Investigative site
France, France - Investigative Site
Iceland, Iceland - (and 6 more...)
|
|
| 54 |
NCT03174002 |
Recruiting |
Handling Oxygenation Targets in the Intensive Care Unit |
- Hypoxemic Respiratory Failure
- Oxygen Toxicity
|
|
Interventional
|
Phase 4 |
- Aalborg Universitetshospital
- Rigshospitalet, Denmark
- Copenhagen Trial Unit, Center for Clinical Intervention Research
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mortality
- Days alive without organ support
- Days alive out of the hospital
- (and 4 more...)
|
2928 |
All |
18 Years and older (Adult, Older Adult) |
NCT03174002 |
AAUH-ICU-01
2017-000632-34 |
HOT-ICU |
June 19, 2017 |
September 15, 2019 |
June 15, 2020 |
June 2, 2017 |
April 4, 2018 |
|
- Dept. of Intensive Care, Aalborg University Hospital
Aalborg, Denmark - Dept. of Intensive Care, Aarhus University Hospital Nørrebrogade
Aarhus, Denmark - Dept. of Intensive Care, Aarhus University Hospital Tage Hansensgade
Aarhus, Denmark - (and 27 more...)
|
|
| 55 |
NCT03131453 |
Recruiting |
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease |
|
- Drug: CNP520 50mg
- Drug: CNP520 15mg
- Other: Placebo to CNP520
|
Interventional
|
Phase 2
Phase 3 |
- Novartis Pharmaceuticals
- Amgen
- Banner Alzheimer's Institute
- Novartis
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to event
- Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score
- Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score
- (and 9 more...)
|
2000 |
All |
60 Years to 75 Years (Adult, Older Adult) |
NCT03131453 |
CCNP520A2202J
2016-002976-28 |
Generation S2 |
August 3, 2017 |
July 30, 2024 |
March 31, 2025 |
April 27, 2017 |
October 17, 2018 |
|
- Banner Alzheimer's Institute, 901 East Willetta Street
Phoenix, Arizona, United States - Novartis Investigative Site
Scottsdale, Arizona, United States - Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Building B
Sun City, Arizona, United States - (and 151 more...)
|
|
| 56 |
NCT02914600 |
Enrolling by invitation |
Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease |
|
- Drug: Filgotinib
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Safety Profile of Filgotinib Evaluated by the Percentage of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory Tests
- Change from Baseline in PRO2 Scores
- Change from Baseline in Crohn's Disease Activity Index (CDAI) Scores
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02914600 |
GS-US-419-3896
2016-002763-34 |
DIVERSITYLTE |
March 17, 2017 |
September 2022 |
October 2022 |
September 26, 2016 |
October 11, 2018 |
|
- Digestive Health Specialists of SE
Dothan, Alabama, United States - Mayo Clinic
Scottsdale, Arizona, United States - Tibor Rubin VA Medical Center
Corona, California, United States - (and 457 more...)
|
|
| 57 |
NCT02914561 |
Recruiting |
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease |
|
- Drug: Filgotinib
- Drug: Placebo to match filgotinib
|
Interventional
|
Phase 3 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Induction Study: Proportion of Participants Achieving Clinical Remission by Patient Reported Outcomes (PRO2) at Week 10
- Induction Study: Proportion of Participants Achieving Endoscopic Response at Week 10
- Maintenance Study: Proportion of Participants Achieving Clinical Remission by PRO2 at Week 58
- (and 9 more...)
|
1320 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02914561 |
GS-US-419-3895
2016-001367-36 |
Diversity1 |
October 2016 |
November 2019 |
December 2019 |
September 26, 2016 |
September 20, 2018 |
|
- Digestive Health Specialists of SE
Dothan, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Tibor Rubin VA Medical Center
Corona, California, United States - (and 475 more...)
|
|
| 58 |
NCT02914535 |
Enrolling by invitation |
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis |
|
- Drug: Filgotinib
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Safety Profile of Filgotinib Evaluated by Proportion of Participants Experiencing Adverse Events and Abnormal Clinical Laboratory Tests
- Change From Baseline in Components of Mayo Clinic Score (MCS)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02914535 |
GS-US-418-3899
2016-002765-58 |
SELECTIONLTE |
February 23, 2017 |
September 2022 |
October 2022 |
September 26, 2016 |
September 14, 2018 |
|
- Digestive Health Specialists Of The Southeast
Dothan, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Tibor Rubin VA Medical Center
Long Beach, California, United States - (and 432 more...)
|
|
| 59 |
NCT02914522 |
Recruiting |
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis |
|
- Drug: Filgotinib
- Drug: Placebo to match filgotinib
|
Interventional
|
Phase 3 |
- Gilead Sciences
- Galapagos NV
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Induction Study: Proportion of Participants Achieving Remission Based on Components of Mayo Clinic Score (MCS) at Week 10
- Maintenance Study: Proportion of Participants Achieving Remission Based on Components of MCS at Week 58
- Induction Study: Proportion of Participants Achieving MCS Remission at Week 10
- (and 11 more...)
|
1300 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02914522 |
GS-US-418-3898
2016-001392-78 |
SELECTION1 |
November 14, 2016 |
November 2019 |
December 2019 |
September 26, 2016 |
September 13, 2018 |
|
- Digestive Health Specialists of the Southeast
Dothan, Alabama, United States - Mayo Clinic Arizona
Scottsdale, Arizona, United States - Tibor Rubin VA Medical Center
Corona, California, United States - (and 448 more...)
|
|
| 60 |
NCT02826603 |
Completed |
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis |
|
- Drug: Secukinumab
- Drug: Ustekinumab
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Psoriasis Area and Severity Index (PASI) 90
- Investigator's Global Assessment (IGA) mod 2011 0/1
- Psoriasis Area and Severity Index (PASI)
- (and 2 more...)
|
1113 |
All |
18 Years and older (Adult, Older Adult) |
NCT02826603 |
CAIN457A2326
2015-002898-37 |
CLARITY |
June 22, 2016 |
July 9, 2018 |
July 9, 2018 |
July 11, 2016 |
August 14, 2018 |
|
- Novartis Investigative Site
Anniston, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - (and 151 more...)
|
|
| 61 |
NCT02825134 |
Recruiting |
Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis |
- Aortic Valve Stenosis
- Cardiovascular Diseases
- Heart Diseases
- (and 2 more...)
|
- Device: Transcatheter aortic valve replacement
- Device: Surgical aortic valve replacement
|
Interventional
|
Not Applicable |
- Rigshospitalet, Denmark
- Symetis SA
- Boston Scientific Corporation
- St. Jude Medical
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Composite rate of all-cause mortality, myocardial infarction and stroke
- Device success (Absence of procedural mortality, correct positioning of a single valve into the proper anatomical location AND intended performanace of the prosthetic heart valve)
- Procedure time
- (and 17 more...)
|
992 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02825134 |
H-15019580 |
NOTION-2 |
June 2016 |
June 2020 |
June 2024 |
July 7, 2016 |
July 7, 2016 |
|
- Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark - Odense University Hospital
Odense, Denmark - Aalborg University Hospital
Ålborg, Denmark - (and 19 more...)
|
|
| 62 |
NCT02788214 |
Recruiting |
Helicobacter Pylori Genome Project |
- Gastric Cancer
- Non-Atrophic Gastritis
- Intestinal Metaplasia
|
|
Observational
|
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Cross-Sectional
|
|
2000 |
All |
35 Years to 70 Years (Adult, Older Adult) |
NCT02788214 |
999916120
16-C-N120 |
|
May 28, 2016 |
December 31, 2018 |
September 30, 2020 |
June 2, 2016 |
August 9, 2018 |
|
- Arctic Investigations Program, CDC
Anchorage, Alaska, United States - White River Medical Center
Batesville, Arkansas, United States - Vanderbilt University Medical Center
Nashville, Tennessee, United States - (and 39 more...)
|
|
| 63 |
NCT02780297 |
Recruiting |
Prospective Research Rare Kidney Stones (ProRKS) |
- Hyperoxaluria
- Cystinuria
- Dent Disease
- (and 2 more...)
|
|
Observational
|
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- inflammatory blood and urinary biomarkers
- Longitudinal changes in eGFR
|
220 |
All |
Child, Adult, Older Adult |
NCT02780297 |
16-000494 |
ProRKS |
May 2016 |
July 2024 |
July 2024 |
May 23, 2016 |
October 10, 2017 |
|
- University of Alabama @ Birmingham
Birmingham, Alabama, United States - Mayo Clinic Jacksonville
Jacksonville, Florida, United States - Children's Memorial Hospital
Chicago, Illinois, United States - (and 8 more...)
|
|
| 64 |
NCT02752737 |
Recruiting |
Cryo AF Global Registry |
|
|
Observational
|
|
- Medtronic Cardiac Rhythm and Heart Failure
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Freedom from Atrial Fibrillation (AF) Recurrence at 12 Months
- Freedom from Atrial Arrhythmia at 12 Months
- Freedom from Device / Procedure Related Adverse Events
|
3000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02752737 |
Cryo AF Global Registry |
|
May 2016 |
December 2022 |
December 2024 |
April 27, 2016 |
September 26, 2018 |
|
- Institituo Cardiovascular Buenos Aires (ICBA)
Buenos Aires, Argentina - Hospital Universitario Fundación Favaloro
Buenos Aires, Argentina - Kepler Universitätsklinikum Med Campus III.
Linz, Austria - (and 56 more...)
|
|
| 65 |
NCT02748863 |
Completed |
Study of Secukinumab With 2 mL Pre-filled Syringes |
|
- Drug: Placebo
- Drug: Secukinumab 2 mL form
- Drug: Secukinumab 1 mL form
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- PASI 75 and IGA mod 2011 0 or 1 response after 12 weeks of treatment
- PASI 90 and PASI 100 response after 12 weeks of treatment
- PASI 100 response after 12 weeks of treatment
|
214 |
All |
18 Years and older (Adult, Older Adult) |
NCT02748863 |
CAIN457A2323 |
ALLURE |
December 12, 2016 |
August 8, 2017 |
June 8, 2018 |
April 22, 2016 |
September 26, 2018 |
|
- Novartis Investigative Site
Phoenix, Arizona, United States - Novartis Investigative Site
Fountain Valley, California, United States - Novartis Investigative Site
Fremont, California, United States - (and 49 more...)
|
|
| 66 |
NCT02745080 |
Recruiting |
Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis |
|
- Biological: Secukinumab
- Biological: Adalimumab
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- American College of Rheumatology 20 (ACR20) response
- PASI90
- ACR50 response
- (and 2 more...)
|
850 |
All |
18 Years and older (Adult, Older Adult) |
NCT02745080 |
CAIN457F2366 |
EXCEED 1 |
January 8, 2017 |
September 4, 2019 |
December 24, 2019 |
April 20, 2016 |
October 11, 2018 |
|
- Novartis Investigative Site
Fountain Valley, California, United States - Novartis Investigative Site
Fullerton, California, United States - Novartis Investigative Site
La Mesa, California, United States - (and 184 more...)
|
|
| 67 |
NCT02699736 |
Enrolling by invitation |
Clinical and Virological Outcome of European Patients Infected With HIV |
- HIV
- Hepatitis B
- Hepatitis C
- (and 10 more...)
|
|
Observational
|
|
- Rigshospitalet, Denmark
- University College, London
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of long-term virological, immunological and morbidity and mortality outcomes across different regions in Europe; and demographic, clinical, therapeutic and viral factors associated with these outcomes
- Number of patients experiencing HIV-related events over time
- Number of participants experiencing HIV-related events by region
- (and 7 more...)
|
20852 |
All |
16 Years and older (Child, Adult, Older Adult) |
NCT02699736 |
The EuroSIDA Study
QLK2-2000-00773
LSHC-CT-2006-018632
Gilead EuroSIDA
GSK EuroSIDA
Janssen EuroSIDA
CT94-1637
CT97-2713
Pfizer EuroSIDA
Merck EuroSIDA
BMS EuroSIDA
SNSF 108787 |
EuroSIDA |
January 1994 |
December 2030 |
December 2030 |
March 4, 2016 |
April 27, 2018 |
|
- Hospital JM Ramos Mejia
Buenos Aires, Argentina - Medical University Insbruck
Innsbruck, Austria - Otto Wagner Spital
Vienna, Austria - (and 107 more...)
|
|
| 68 |
NCT02555683 |
Recruiting |
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. |
|
- Drug: QAW039
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Moderate-to-severe asthma exacerbations
- Asthma Quality of Life Questionnaire+12 (AQLQ+12) score
- Asthma Control Questionnaire-5 (ACQ-5) score
- (and 2 more...)
|
846 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02555683 |
CQAW039A2307
2015-002553-35 |
|
December 11, 2015 |
December 20, 2019 |
December 20, 2019 |
September 21, 2015 |
October 15, 2018 |
|
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Gilbert, Arizona, United States - (and 253 more...)
|
|
| 69 |
NCT02549001 |
Completed |
Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis |
|
- Drug: P-3058 10%
- Drug: vehicle of P-3058 10%
- Drug: amorolfine 5%
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Complete cure of target great toenail defined as negative KOH microscopy, negative culture for dermatophytes and target nail totally clear.
- Responder rate of the target toenail, defined as negative KOH microscopy, negative culture for dermatophytes and ≤10% residual involvement of the target toenail.
- Negative culture rate for dermatophytes of the target nail.
- (and 2 more...)
|
953 |
All |
12 Years and older (Child, Adult, Older Adult) |
NCT02549001 |
PM1331
2015-000561-31 |
|
August 20, 2015 |
September 17, 2018 |
September 17, 2018 |
September 14, 2015 |
September 26, 2018 |
|
- Polichem Investigative Site
Multiple Locations, Belgium - Polichem Investigative Site
Multiple Locations, Bulgaria - Polichem Investigative Site
Multiple Locations, Czechia - (and 10 more...)
|
|
| 70 |
NCT02536118 |
Recruiting |
Micra Transcatheter Pacing System Post-Approval Registry |
|
- Device: Micra Transcatheter Pacing System
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Acute complication rate
- Long-term complication free survival
- Pacing impedance (ohms) and pacing threshold (volts)
- (and 4 more...)
|
3100 |
All |
Child, Adult, Older Adult |
NCT02536118 |
Micra Registry |
|
July 2015 |
August 2026 |
August 2026 |
August 31, 2015 |
January 23, 2018 |
|
- Birmingham, Alabama, United States
- Los Angeles, California, United States
- Redwood City, California, United States
- (and 153 more...)
|
|
| 71 |
NCT02485691 |
Recruiting |
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent |
- Prostate Cancer Metastatic
|
- Drug: cabazitaxel XRP6258
- Drug: enzalutamide
- Drug: abiraterone acetate
- Drug: prednisone
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Radiographic progression-free survival defined as the time from randomization to the occurrence of radiological tumor progressions using RECIST 1.1 and progression of bone lesions using Prostate Cancer Working Group 2 (PCWG2) criteria
- Radiographic progression-free survival defined as the time from randomization to the occurrence of death due to any cause
- Number of patients achieving PSA decline >=50%
- (and 11 more...)
|
234 |
Male |
18 Years and older (Adult, Older Adult) |
NCT02485691 |
LPS14201
2014-004676-29
U1111-1166-5329 |
CARD |
November 9, 2015 |
August 2019 |
August 2019 |
June 30, 2015 |
August 1, 2018 |
|
- Investigational Site Number 040002
Linz, Austria - Investigational Site Number 040003
Wien, Austria - Investigational Site Number 040004
Wien, Austria - (and 83 more...)
|
|
| 72 |
NCT02481817 |
Active, not recruiting |
Treatment Alternatives in iSGS (NoAAC PR-02 Study) |
- Idiopathic Subglottic Stenosis (iSGS)
|
- Procedure: Endoscopic dilation of subglottic stenosis
- Procedure: Endoscopic resection of the stenosis
- Procedure: Tracheal Resection
|
Observational
|
|
- Vanderbilt University Medical Center
- Patient-Centered Outcomes Research Institute
- The Cleveland Clinic
- (and 41 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Treatment Effectiveness: Time to recurrent procedure
- Treatment Effectiveness: Need for tracheostomy
- QOL
- Patient Reported Outcome
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02481817 |
150917 |
NoAAC PR-02 |
August 28, 2015 |
October 2018 |
October 2019 |
June 25, 2015 |
May 8, 2018 |
|
- The University of Alabama at Birmingham
Birmingham, Alabama, United States - Mayo Clinic
Scottsdale, Arizona, United States - University of California Irvine
Irvine, California, United States - (and 39 more...)
|
|
| 73 |
NCT02404389 |
Completed
Has Results |
Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients |
|
- Drug: Investigational Treatment
- Drug: Active comparator
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Adverse Events (AE)/Serious Adverse Events (SAE) as a Measure of Safety and Tolerability up to 20 Weeks
- Number of Participants That Had Complete Clearance of Actinic Keratosis (AK) at 8 Weeks After the End of Treatment (Week 20) for LFX453 Compared to Vehicle Groups Combined
- Reduction Rate (Percent) of Actinic Keratosis (AK) Lesion Count at 8 Weeks After the End of Treatment (Week 20) for LFX453 Compared to Vehicle Groups Combined
- (and 4 more...)
|
82 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02404389 |
CLFX453X2201 |
|
March 5, 2015 |
January 27, 2016 |
January 27, 2016 |
March 31, 2015 |
March 19, 2018 |
March 19, 2018 |
- Novartis Investigative Site
Vienna, Austria - Novartis Investigative Site
Copenhagen NV, Denmark - Novartis Investigative Site
Berlin, Germany - (and 7 more...)
|
|
| 74 |
NCT01566929 |
Completed |
Weight Management Intervention for Obese Women and the Live Birth Outcome of in Vitro Fertilization (IVF) |
|
- Dietary Supplement: Low calorie diet treatment
|
Interventional
|
Not Applicable |
- Sahlgrenska University Hospital, Sweden
- Karolinska University Hospital
- Skane University Hospital
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Live birth
- embryology
- obstetric outcomes
- (and 2 more...)
|
317 |
Female |
18 Years to 37 Years (Adult) |
NCT01566929 |
Obesity/IVF |
|
October 2010 |
January 2016 |
April 2018 |
March 30, 2012 |
September 7, 2018 |
|
- Herlev hospital
Copenhagen, Denmark - Hvidovre hospital
Copenhagen, Denmark - Rigshospitalet
Copenhagen, Denmark - (and 6 more...)
|
|
| 75 |
NCT02304484 |
Completed |
Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Low density lipoprotein cholesterol (LDL-C) at week 52
|
770 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT02304484 |
20140128
2014-001524-30 |
|
November 24, 2014 |
March 9, 2018 |
March 9, 2018 |
December 2, 2014 |
April 26, 2018 |
|
- Research Site
Huntsville, Alabama, United States - Research Site
Mobile, Alabama, United States - Research Site
Long Beach, California, United States - (and 123 more...)
|
|
| 76 |
NCT02188355 |
Recruiting |
Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry |
|
|
Observational
|
|
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- TLF
- success endpoints
- safety endpoints
- efficacy and patient oriented (composite) endpoints
|
37000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02188355 |
T123E2 |
e-Ultimaster |
October 2014 |
September 2018 |
September 2019 |
July 11, 2014 |
August 3, 2017 |
|
- Fundación Favaloro
Buenos Aires, Argentina - Instituto Cardiovascular de Buenos Aires
CABA - Buenos Aires, Argentina - QANCOR Cardiovascular MC LLC
Yerevan, Armenia - (and 340 more...)
|
|
| 77 |
NCT02102165 |
Recruiting |
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer. |
|
- Procedure: metastatic lesion biopsy
|
Interventional
|
Not Applicable |
- Breast International Group
- Breast European Adjuvant Studies Team
- Frontier Science & Technology Research Foundation, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Metastatic Breast Cancer (MBC) understanding
- Building new therapeutic hypotheses
- Patients' prognosis determination
- (and 4 more...)
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT02102165 |
BIG 14-01
1408-BCG
GBG 85
ICR-CTSU/2014/10050 |
AURORA |
April 2014 |
April 2019 |
January 2029 |
April 2, 2014 |
March 22, 2018 |
|
- Institut Jules Bordet
Brussels, Belgium - Cliniques Universitaires St-Luc
Brussels, Belgium - Grand Hopital Charleroi
Charleroi, Belgium - (and 57 more...)
|
|
| 78 |
NCT01838746 |
Unknown † |
CRAGS (Coronary aRtery diseAse in younG adultS) |
- Coronary Artery Disease
- Acute Coronary Syndromes
- Young Patient
- (and 2 more...)
|
|
Observational
|
|
- University of Turku
- Finnish Foundation for Cardiovascular Research
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Repeat revascularization
- All-cause mortality
- Major cardiovascular and cerebral events (MACCE)
- (and 2 more...)
|
2000 |
All |
18 Years to 50 Years (Adult) |
NCT01838746 |
CRAGS-1 |
CRAGS |
April 2013 |
December 2014 |
December 2016 |
April 24, 2013 |
May 28, 2015 |
|
- Oulu University Hospital
Oulu, Finland - Satakunta Central Hospital
Pori, Finland - Tampere University Hospital
Tampere, Finland - (and 6 more...)
|
|
| 79 |
NCT02064868 |
Terminated |
Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients |
- Acute Heart Failure (AHF)
|
- Drug: Serelaxin
- Drug: Standard of Care
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from baseline in worsening HF (WHF) requiring rescue therapy or all cause death, through Day 5
- Change from baseline in worsening HF (WHF) requiring rescue therapy or all cause death or readmission for heart failure and or renal failure through day 14
- Change from baseline in the number of patients with persistent symptoms or signs of Heart Failure (HF) or not showing improvement (persisting need of Intravenous therapy for HF)
- (and 4 more...)
|
2653 |
All |
18 Years and older (Adult, Older Adult) |
NCT02064868 |
CRLX030A3301
2013-002513-35 |
RELAX-AHF-EU |
January 31, 2014 |
March 26, 2017 |
April 25, 2017 |
February 17, 2014 |
November 17, 2017 |
|
- Novartis Investigative Site
Feldkirch, Austria - Novartis Investigative Site
Graz, Austria - Novartis Investigative Site
Linz, Austria - (and 355 more...)
|
|
| 80 |
NCT02032823 |
Recruiting |
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer |
|
- Drug: Olaparib
- Drug: Placebo
|
Interventional
|
Phase 3 |
- AstraZeneca
- Breast International Group
- Frontier Science & Technology Research Foundation, Inc.
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Invasive Disease Free Survival (IDFS)
- Overall survival (OS)
- Distant Disease Free Survival (DDFS)
- (and 4 more...)
|
1800 |
All |
18 Years to 130 Years (Adult, Older Adult) |
NCT02032823 |
D081CC00006
NSABP B-55
BIG 6-13 |
OlympiA |
April 22, 2014 |
November 30, 2020 |
November 27, 2028 |
January 10, 2014 |
October 2, 2018 |
|
- Research Site
Anchorage, Alabama, United States - Research Site
Anchorage, Alaska, United States - Research Site
Anchorage, Alaska, United States - (and 1287 more...)
|
|
| 81 |
NCT00706134 |
Completed
Has Results |
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study |
|
- Drug: Placebo
- Drug: Aliskiren 75 mg
- Drug: Aliskiren 150 mg
- Drug: Aliskiren 300 mg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Mean Sitting Systolic Blood Pressure (msSBP)From Baseline to End of Study (Week 8)
- Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
- Percentage of Patients Achieving Systolic Blood Pressure Response
- (and 3 more...)
|
756 |
All |
65 Years and older (Older Adult) |
NCT00706134 |
CSPP100A2405 |
|
May 2008 |
April 2009 |
April 2009 |
June 27, 2008 |
June 28, 2011 |
June 17, 2011 |
- Investigative Site
Buenos Aires, Argentina - Investigative Site
Prague, Czech Republic - Investigative Site
Berlin, Germany - (and 5 more...)
|
|
| 82 |
NCT01905592 |
Active, not recruiting |
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients |
- Carcinoma of Breast
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- BRCA1 Gene Mutation
- BRCA2 Gene Mutation
|
- Drug: niraparib
- Drug: Physician's choice
|
Interventional
|
Phase 3 |
- Tesaro, Inc.
- European Organisation for Research and Treatment of Cancer - EORTC
- Breast International Group
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- Overall survival
|
306 |
All |
18 Years and older (Adult, Older Adult) |
NCT01905592 |
PR-30-5010-C
1307-BCG, BIG5-13 |
BRAVO |
October 2013 |
May 2018 |
May 2018 |
July 23, 2013 |
November 6, 2017 |
|
- Tucson, Arizona, United States
- Los Angeles, California, United States
- Fort Myers, Florida, United States
- (and 94 more...)
|
|
| 83 |
NCT01828489 |
Recruiting |
Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years |
- Pediatric Acute Myeloblastic Leukemia
|
- Drug: Randomisation course 1 mitoxantrone versus DaunoXome
- Drug: Randomisation course 2 ADxE versus FLADx
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Minimal residual disease
- Event-free survival
- Acute toxicity
- (and 2 more...)
|
300 |
All |
up to 18 Years (Child, Adult) |
NCT01828489 |
NOPHO-DBH-AML2012
2012-002934-35 |
AML2012 |
March 2013 |
March 2018 |
March 2023 |
April 10, 2013 |
January 10, 2017 |
|
- HUDERF, L'Hôpital des Enfants Hématologie / Oncologie
Brussel, Belgium - UZ Brussel, Pediatrische Hemato-Oncologie F930
Brussel, Belgium - UCL, Cliniques Universitaires Saint-Luc
Brussel, Belgium - (and 29 more...)
|
|
| 84 |
NCT01813422 |
Completed
Has Results |
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound |
|
- Biological: Evolocumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Percent Atheroma Volume at Week 78
- Change From Baseline in Total Atheroma Volume at Week 78
- Percentage of Participants With Regression in Percent Atheroma Volume
- Percentage of Participants With Regression in Total Atheroma Volume
|
970 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01813422 |
20120153
2012-004208-37 |
GLAGOV |
April 18, 2013 |
July 12, 2016 |
July 29, 2016 |
March 19, 2013 |
June 7, 2018 |
January 4, 2018 |
- Research Site
Huntsville, Alabama, United States - Research Site
Mobile, Alabama, United States - Research Site
Little Rock, Arkansas, United States - (and 223 more...)
|
|
| 85 |
NCT01782326 |
Completed
Has Results |
QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations) |
- Chronic Obstructive Pulmonary Disease (COPD)
|
- Drug: QVA149
- Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Rate of COPD Exacerbations
- Time to First COPD Exacerbation.
- Rate of Moderate to Severe COPD Exacerbations.
- (and 16 more...)
|
3362 |
All |
40 Years and older (Adult, Older Adult) |
NCT01782326 |
CQVA149A2318 |
|
July 2013 |
September 2015 |
September 2015 |
February 1, 2013 |
May 16, 2016 |
May 16, 2016 |
- Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Caba, Buenos Aires, Argentina - (and 493 more...)
|
|
| 86 |
NCT01702571 |
Active, not recruiting |
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment |
|
- Drug: Trastuzumab Emtansine
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Progression-Free Survival According to Response Evaluation for Solid Tumors (RECIST) Version (v) 1.1 As Per Investigator Assessment
- Overall Survival According to RECIST v 1.1 As Per Investigator Assessment
- (and 4 more...)
|
2003 |
All |
18 Years and older (Adult, Older Adult) |
NCT01702571 |
MO28231
2012-001628-37 |
|
November 27, 2012 |
October 21, 2016 |
September 30, 2019 |
October 8, 2012 |
September 11, 2017 |
|
- CEMIC
Buenos Aires, Argentina - Centro Oncologico Riojano Integral (CORI)
La Rioja, Argentina - Hospital Privado De Comunidad; General Practice
Mar Del Plata, Argentina - (and 303 more...)
|
|
| 87 |
NCT00992641 |
Completed |
The Effect of Nordic Recommended Diet on the Features of Metabolic Syndrome - Multicentre Study |
- Abdominal Obesity
- Insulin Resistance
- Impaired Glucose Tolerance
- (and 2 more...)
|
- Other: Experimental diet
- Other: Control diet
|
Interventional
|
Not Applicable |
- Marjukka Kolehmainen
- University of Copenhagen
- Aarhus University Hospital
- (and 6 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Glucose metabolism
- Transcriptomics and metabolomics data
|
167 |
All |
30 Years to 65 Years (Adult, Older Adult) |
NCT00992641 |
SYSDIET 070014
31//2009 |
SYSDIET |
August 2009 |
November 2010 |
December 2011 |
October 9, 2009 |
April 17, 2012 |
|
- Aarhus University
Aarhus, Denmark - University of Copenhagen
Copenhagen, Denmark - University of Kuopio
Kuopio, Finland - (and 5 more...)
|
|
| 88 |
NCT01592786 |
Completed
Has Results |
An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) |
- Autism Spectrum Disorder (ASD)
- Autism
- Autistic Disorder
- (and 4 more...)
|
- Drug: Memantine Hydrochloride (HCl)
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Confirmed Social Responsiveness Scale (SRS) Responders
|
906 |
All |
6 Years to 12 Years (Child) |
NCT01592786 |
MEM-MD-91 |
|
June 2012 |
July 2013 |
August 2013 |
May 7, 2012 |
August 7, 2014 |
August 7, 2014 |
- Forest Investigative Site 068
Dothan, Alabama, United States - Forest Investigative Site 005
Phoenix, Arizona, United States - Forest Investigative Site 055
Tucson, Arizona, United States - (and 115 more...)
|
|
| 89 |
NCT01592773 |
Terminated
Has Results |
Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) |
- Autism Spectrum Disorder (ASD)
- Autism
- Autistic Disorder
- (and 4 more...)
|
- Drug: Memantine Hydrochloride (HCl)
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Patients With Any Treatment-emergent Adverse Event
|
747 |
All |
6 Years to 12 Years (Child) |
NCT01592773 |
MEM-MD-69 |
|
October 2012 |
January 2014 |
March 2014 |
May 7, 2012 |
February 16, 2015 |
February 16, 2015 |
- Forest Investigative Site 068
Dothan, Alabama, United States - Forest Investigative Site 005
Phoenix, Arizona, United States - Forest Investigative Site 055
Tucson, Arizona, United States - (and 103 more...)
|
|
| 90 |
NCT01592747 |
Completed |
Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine |
- Autism Spectrum Disorder (ASD)
- Autism
- Autistic Disorder
- (and 5 more...)
|
- Drug: Memantine Hydrochloride (HCl)
- Drug: Placebo capsules
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary outcome measure in this study will be the proportion of patients meeting the criterion for Loss of Therapeutic Response (LTR) by the end of the study.
- Children's Communication Checklist-2 (CCC-2)
- Time to the first visit when a patient shows LTR following randomization to memantine or placebo (time to the first LTR)
|
480 |
All |
6 Years to 12 Years (Child) |
NCT01592747 |
MEM-MD-68 |
|
September 2012 |
September 2013 |
October 2013 |
May 7, 2012 |
November 4, 2013 |
|
- Forest Investigative Site 068
Dothan, Alabama, United States - Forest Investigative Site 005
Phoenix, Arizona, United States - Forest Investigative Site 055
Tucson, Arizona, United States - (and 128 more...)
|
|
| 91 |
NCT01544595 |
Completed |
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab |
- Moderate to Severe Plaque-type Psoriasis
|
- Drug: Secukinumab (AIN457)
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cumulative rate of subjects with Loss of Psoriasis Area and Severity Index (PASI) 75 response up to Week 68
- Change in Psoriasis Area and Severity Index (PASI)
- Investigator Global Assessment (IGA) 2011 score
- (and 5 more...)
|
1150 |
All |
18 Years and older (Adult, Older Adult) |
NCT01544595 |
CAIN457A2302E1
2012-000533-39 |
|
August 15, 2004 |
June 26, 2017 |
June 26, 2017 |
March 6, 2012 |
April 9, 2018 |
|
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Phoenix, Arizona, United States - (and 179 more...)
|
|
| 92 |
NCT00376792 |
Unknown † |
Docetaxel Compared With Observation in Treating Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer |
|
- Drug: docetaxel
- Other: active surveillance
- Procedure: adjuvant therapy
|
Interventional
|
Phase 3 |
- Scandinavian Prostate Cancer Group
- National Cancer Institute (NCI)
|
Other |
- Allocation: Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Prostate-specific antigen (PSA) progression
- PSA doubling time
- Quality of Life
- (and 2 more...)
|
396 |
Male |
18 Years to 70 Years (Adult, Older Adult) |
NCT00376792 |
CDR0000456773
SPCG-12
EUDRACT-2005-002355-40
EU-20638
SANOFI-AVENTIS-SPCG-12
SPCG-ADPRO |
|
October 2005 |
December 2012 |
|
September 15, 2006 |
August 26, 2013 |
|
- Aarhus Universitetshospital - Aarhus Sygehus
Aarhus, Denmark - Copenhagen County Herlev University Hospital
Copenhagen, Denmark - Tampere University Hospital
Tampere, Finland - (and 5 more...)
|
|
| 93 |
NCT01524276 |
Recruiting |
Product Surveillance Registry |
- Cardiac Rhythm Disorders
- Sacral Neuromodulation
- Neurological Disorders
- (and 2 more...)
|
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Safety and Effectiveness of Market Released products
|
90000 |
All |
Child, Adult, Older Adult |
NCT01524276 |
PSR |
PSR |
January 2012 |
January 2030 |
January 2030 |
February 1, 2012 |
September 21, 2018 |
|
- Birmingham, Alabama, United States
- Anchorage, Alaska, United States
- Chandler, Arizona, United States
- (and 252 more...)
|
|
| 94 |
NCT01517178 |
Terminated
Has Results |
Multi-national, Safety and Performance Study of New Ostomy Product Compared to Standard Care |
|
- Device: New ostomy base plate (SS)
- Device: Standard Care base plate
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Degree of Output Under the Base Plate (Leakage).
|
33 |
All |
18 Years and older (Adult, Older Adult) |
NCT01517178 |
CP215OC |
|
May 2011 |
June 2011 |
June 2011 |
January 25, 2012 |
March 13, 2015 |
March 13, 2015 |
- Sygehus Sønderjylland i Aabenraa
Aabenraa, Denmark - Bispebjerg Hospital
Copenhagen, Denmark - Hvidovre Hospital
Hvidovre, Denmark - (and 8 more...)
|
|
| 95 |
NCT01468077 |
Completed
Has Results |
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment |
|
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants With Any Infusion Reaction
- Percentage of Participants Discontinuing Tocilizumab in Response to an AE or a Serious Adverse Event (SAE)
- Percentage of Participants Discontinuing Tocilizumab for Other Reasons
- (and 13 more...)
|
47 |
All |
18 Years and older (Adult, Older Adult) |
NCT01468077 |
ML27901 |
|
November 2011 |
September 2013 |
September 2013 |
November 9, 2011 |
August 17, 2015 |
August 17, 2015 |
- Alborg, Denmark
- Frederiksberg, Denmark
- Hellerup, Denmark
- (and 5 more...)
|
|
| 96 |
NCT01369355 |
Active, not recruiting
Has Results |
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) |
- Crohn's Disease
- Colitis
- IBD
- Inflammatory Bowel Disease
|
- Drug: Placebo SC
- Drug: Placebo IV
- Drug: Ustekinumab 90 mg SC q8w
- (and 2 more...)
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Clinical Remission at Week 44
- Number of Participants With Clinical Response at Week 44
- Number of Participants in Clinical Remission at Week 44 Among Participants in Clinical Remission to Ustekinumab at Week 0 of Maintenance Study
- (and 2 more...)
|
1282 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01369355 |
CR018421
CNTO1275CRD3003
2010-022760-12 |
|
September 13, 2011 |
June 10, 2015 |
October 21, 2019 |
June 8, 2011 |
September 6, 2018 |
February 23, 2017 |
- Tucson, Arizona, United States
- La Jolla, California, United States
- Los Angeles, California, United States
- (and 218 more...)
|
|
| 97 |
NCT01369342 |
Completed
Has Results |
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) |
- Crohn's Disease
- Inflammatory Bowel Disease
- IBD
- Colitis
|
- Drug: Group 1: Placebo
- Drug: Group 2 ustekinumab 130 mg
- Drug: Group 3: ustekinumab approximately 6 mg/kg
|
Interventional
|
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Clinical Response at Week 6
- Number of Participants in Clinical Remission at Week 8
- Number of Participants in Clinical Response at Week 8
- (and 2 more...)
|
640 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT01369342 |
CR018418
CNTO1275CRD3002
2010-022759-42 |
|
July 2011 |
August 2014 |
October 2014 |
June 8, 2011 |
January 6, 2017 |
January 6, 2017 |
- Tucson, Arizona, United States
- Little Rock, Arkansas, United States
- La Jolla, California, United States
- (and 221 more...)
|
|
| 98 |
NCT01365455 |
Completed
Has Results |
Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year |
- Moderate to Severe Plaque-type Psoriasis
|
- Drug: secukinumab 150 mg
- Drug: placebo to secukinumab 150 mg
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks
- Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1
- Percentage of Participants Who Achieved a PASI (Psoriasis Area and Severity Index) Score of 90 or Better at Week 12
- (and 18 more...)
|
738 |
All |
18 Years and older (Adult, Older Adult) |
NCT01365455 |
CAIN457A2302
2010-023512-13 |
ERASURE |
June 2011 |
April 2013 |
April 2013 |
June 3, 2011 |
February 17, 2016 |
May 29, 2015 |
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Phoenix, Arizona, United States - (and 85 more...)
|
|
| 99 |
NCT01358578 |
Completed
Has Results |
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis |
|
- Drug: Placebo
- Drug: secukinumab (AIN457)
- Drug: etanercept
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) .
- Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12
- Efficacy of Secukinumab Compared to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 90 at Week 12
- (and 7 more...)
|
1306 |
All |
18 Years and older (Adult, Older Adult) |
NCT01358578 |
CAIN457A2303
2010-022228-66 |
FIXTURE |
June 2011 |
July 2013 |
July 2013 |
May 23, 2011 |
February 17, 2016 |
September 23, 2015 |
- Novartis Investigative Site
Birmingham, Alabama, United States - Novartis Investigative Site
Phoenix, Arizona, United States - Novartis Investigative Site
San Diego, California, United States - (and 149 more...)
|
|
| 100 |
NCT01322490 |
Completed |
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer |
- Prostate Cancer Metastatic
|
- Biological: PROSTVAC-V
- Biological: PROSTVAC-F
- Drug: GM-CSF
- (and 2 more...)
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- Proportion of event-free patients compared with placebo
|
1298 |
Male |
18 Years and older (Adult, Older Adult) |
NCT01322490 |
BNIT-PRV-301 |
Prospect |
November 28, 2011 |
September 25, 2017 |
December 15, 2017 |
March 24, 2011 |
January 9, 2018 |
|
- Alaska Clinical Research Center, Llc
Anchorage, Alaska, United States - Scottsdale Healthcare
Scottsdale, Arizona, United States - Alta Bates Summit Medical Center
Berkeley, California, United States - (and 217 more...)
|
|
Create an RSS feed from your search for:
Download the search results for: